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Abstract
ETS gene fusions, which result in overexpression of an ETS transcription factor, are considered driving mutations
in approximately half of all prostate cancers. Dysregulation of ETS transcription factors is also known to exist in
Ewing’s sarcoma, breast cancer, and acute lymphoblastic leukemia. We previously discovered that ERG, the
predominant ETS family member in prostate cancer, interacts with the DNA damage response protein poly
(ADP-ribose) polymerase 1 (PARP1) in human prostate cancer specimens. Therefore, we hypothesized that the
ERG-PARP1 interaction may confer radiation resistance by increasing DNA repair efficiency and that this radio-
resistance could be reversed through PARP1 inhibition. Using lentiviral approaches, we established isogenic
models of ERG overexpression in PC3 and DU145 prostate cancer cell lines. In both cell lines, ERG overexpression
increased clonogenic survival following radiation by 1.25 (±0.07) fold (mean ± SEM) and also resulted in increased
PARP1 activity. PARP1 inhibition with olaparib preferentially radiosensitized ERG-positive cells by a factor of
1.52 (±0.03) relative to ERG-negative cells (P < .05). Neutral and alkaline COMET assays and immunofluorescence
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microscopy assessing γ-H2AX foci showed increased short- and long-term efficiencies of DNA repair, respectively,
following radiation that was preferentially reversed by PARP1 inhibition. These findings were verified in an in vivo
xenograft model. Our findings demonstrate that ERG overexpression confers radiation resistance through
increased efficiency of DNA repair following radiation that can be reversed through inhibition of PARP1. These results
motivate the use of PARP1 inhibitors as radiosensitizers in patients with localized ETS fusion–positive cancers.
Neoplasia (2013) 15, 1207–1217
Introduction
ETS gene fusions represent the most abundant genetic translocation
associated with solid tumors [1,2] and are present in approximately half
of all prostate cancers, the majority of Ewing’s sarcomas, and subsets of
breast cancer and acute lymphoblastic leukemia [1–10]. In prostate
cancers, these gene fusions are thought to be driving mutations and re-
sult in overexpression of the involved ETS transcription factor [1–7].
Whereas ETS gene fusions and the resultant transcription factor over-
expression have been implicated in carcinogenesis and invasion [11–14],
the mechanisms by which they mediate their effects are still being eluci-
dated, as are other phenotypes that may be conferred by these fusions.
We recently discovered that the predominant ETS fusion product
in prostate cancer, ERG, interacts with poly(ADP-ribose) polymerase 1
(PARP1) [15], a DNA repair protein initially implicated in base
excision repair [16,17], but more recently demonstrated to play a role
in homologous recombination [18–20], nonhomologous end-joining
[21–23], and transcriptional regulation [24]. PARP1 mediates its
effects through addition of PAR groups to a subset of nuclear proteins,
thereby helping to initiate DNA repair [25,26]. Radiation therapy (RT)
is a standard treatment option or component of treatment for many
malignancies known to harbor ETS overexpression including prostate
cancer. Whereas RT often provides durable long-term responses, a
substantial number of patients will experience biochemical recurrence
of their disease following treatment, with 5-year rates of biochemical
recurrence of approximately 30% [27]. Thus, a need exists to ascertain
causes of radioresistance that may lead to recurrences as well as to
identify means to improve long-term results following RT. As RT
induces DNA damage that leads to tumor cell death, we hypothesized
that overexpression of ERG, through its interaction with the DNA
repair protein PARP1, would confer radioresistance that would be
preferentially reversible through PARP1 inhibition.
To test this hypothesis, we examined, in vitro, whether overexpression
of ERG resulted in radioresistance, and whether this radioresistance
could be overcome through PARP1 inhibition, and similarly if ERG
overexpression resulted in increased PARP1 activity. We further
assessed the role of ERG inDNA repair and cell cycle distribution, which
are key determinants of response to RT. Finally, we applied our in vitro
findings to an in vivo xenograft model.
Materials and Methods
Cell Culture and Cell Lines
PC3 and DU145 prostate cancer cell lines were grown in RPMI
1640 (Invitrogen, Carlsbad, CA) supplemented with 10% FBS
(Invitrogen) in a 5% CO2 cell culture incubator. All cultures were
alsomaintained with 50 units/ml of penicillin/streptomycin (Invitrogen).
Lentiviruses were generated by the University of Michigan Vector
Core. PC3 or DU145 cells were infected with the following lentiviral
supernatants: pLentilox–CMV-ERG, pLentilox–CMV-ΔETS, pLentilox–
CMV-PARGor pLentilox–CMV-green fluorescent protein (GFP) in the
presence of 4 μg/ml polybrene (Sigma, St Louis, MO). CMV-GFP,
CMV-ΔETS, and CMV-ERG constructs were created as previously de-
scribed (with the CMV-ΔETS and CMV-ERG constructs containing
the most prevalent gene fusion variant) [15], and CMV-PARG was
cloned from a cDNA construct purchased fromGeneCopoeia (Rockville,
MD). Specifically, ΔETS represents an ERG construct in which the
ETS domain (which is necessary for the ERG-PARP1 interaction [15])
has been deleted, and it was used as the control. Stable cell lines were
selected by sorting at the University of Michigan flow cytometry core.
Stable infection was monitored by confirming GFP expression. The
genetic identity of each stable cell line was confirmed by genotyping
samples as previously described [28]. Experiments were conducted on
exponentially growing cells.
PARP Activity Assay
Total protein was isolated from PC3 and DU145 stable cell lines
and quantified by the Bradford assay. Twenty-five micrograms of
protein was then used to assess PARP activity according to themanufac-
turer’s protocol (Trevigen, Gaithersburg, MD; Cat. No. 4677-096-K).
Purified PARP1 enzyme (Trevigen) was used as a positive control for
all reactions.
Clonogenic Survival Assays
Exponentially growing cells were treated with siRNAs [nontargeting
(NT): Cat. No. D-001810-01-20, PARP1: Cat. No. J-006656-07 or
J-006656-08, XRCC1: Cat. No. J009394-06 (Dharmacon, Lafayette,
CO)] or olaparib (Axon Medchem, Groningen, The Netherlands) and
then replated at cloning densities. Cells were grown for 8 days, fixed,
and stained with methanol–acetic acid and crystal violet, respectively,
and scored for colonies of 50 cells or more. Drug cytotoxicity was cal-
culated as the ratio of surviving drug-treated cells relative to untreated
control cells. Radiation survival data from drug-treated cells were
corrected for drug cytotoxicity. Cell survival curves were fit using the
linear-quadratic equation, and the mean inactivation dose was calcu-
lated according to the method of Fertil and colleagues [29]. The radi-
ation enhancement ratio (RER) was calculated as the ratio of the mean
inactivation dose under control conditions divided by the mean inacti-
vation dose under drug-treated conditions.
Immunofluorescence
Cells were cultured on coverslips in 12-well plates and treated with
1.0 μM olaparib (Axon Medchem) for 1 hour and then immediately
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exposed to radiation. Cells were collected at indicated time points
and processed as previously described [15]. Images were collected
with a ×60 objective lens using an Olympus DP70 camera fitted
in an Olympus 1X-71 microscope. The H2AX foci were detected
with mouse monoclonal antibodies phosphor γ-H2AX (Millipore,
Billerica, MA; #JBW301). For quantitation of γ-H2AX foci, at least
100 cells from each of three independent experiments were visually
scored for each condition. Cells with ≥10 γ-H2AX foci were scored
as positive and compared for statistical analyses.
Immunoblot Analysis
Cell pellets and mouse xenografts were lysed and immunoblotted
as previously described [15]. Proteins were detected with anti-PAR
mouse monoclonal antibody (Millipore; Cat. No. MAB3192), anti-
ERG rabbit monoclonal antibody (Epitomics, Burlingame, CA; Cat.
No. 5115-1), anti–PARP-1 polyclonal antibody (Cell Signaling Tech-
nology, Danvers, MA; Cat. No. 9532), PAR glycohydrolase (PARG)
polyclonal antibody (Abcam, Cambridge, MA; Cat. No. ab16060),
XRCC1 antibody (Abcam; Cat. No. 9147), and anti–β-actin mouse
monoclonal antibody (Cell Signaling Technology; Cat. No. 4967).
Single-Cell Gel Electrophoresis
Single-cell gel electrophoresis was performed according to the
manufacturer’s instructions (Trevigen). Briefly, treated or untreated
cells were collected, suspended in ice-cold phosphate-buffered saline
(PBS) at 105 cells/ml, mixed with molten LM agarose (1:10 ratio),
and spread on CometSlide. After the agarose solidified, the slides
were successively placed in lysis and alkaline solutions (Trevigen).
The slides were then subjected to electrophoresis. Cells were fixed with
70% ethanol and stained with SYBR Green. Comet tail moments were
then assessed using COMETScore v1.5 image processing software as
described by the manufacturer (AutoCOMET.com, Sumerduck, VA).
More than 100 cells were analyzed in triplicate experiments. Data
are reported as tail moments, which assess the fluorescence intensity
in the tail relative to the head while accounting for the relative area
of both dipoles.
Statistical Analysis
Results are presented as means ± SEM of at least three experi-
ments. Student’s t test was used to assess the statistical significance
of differences. A significance level threshold of P < .05 was used.
Flow Cytometry
Cells were harvested, washed in cold PBS, fixed in 70% ethanol,
and stained with 50 μg/ml propidium iodide and 100 μg/ml RNase A
in PBS. The cells were analyzed for their DNA content with a FACS.
Irradiation
Irradiation was carried out using a Philips RT250 (Kimtron
Medical, Woodbury, CT) at a dose rate of ∼2 Gy/min in the Uni-
versity of Michigan Comprehensive Cancer Center Experimental
Irradiation Core. Dosimetry was carried out using an ionization
chamber connected to an electrometer system that is directly trace-
able to a National Institute of Standards and Technology calibration.
For tumor irradiation, animals were anesthetized with isoflurane and
positioned such that the apex of each flank tumor was at the center
of a 2.4-cm aperture in the secondary collimator, with the rest of the
mouse shielded from radiation.
Xenograft Models
PC3-control (0.5 × 106 cells) or PC3-ERG (0.5 × 106 cells) stable
cells were suspended in 100 μl of saline with 50% Matrigel (BD
Biosciences, Becton Drive, NJ) and were implanted subcutaneously into
the left flank region of severe combined immunodeficiency (SCID)
mice. Treatment was initiated when the average tumor volume reached
80 mm3. The mice (eight per treatment group) were treated with
ABT-888 (100 mg/kg) twice daily (Abbott, Abbott Park, IL) alone,
radiation alone (2 Gy for 5 days), or in combination. Growth in tumor
volume was recorded three times per week by using digital calipers, and
tumor volumes were calculated using the formula (π/6)(L ×W 2), where
L = length of tumor and W = width. Loss of body weight during the
course of the study was also monitored weekly. All procedures involving
mice were approved by the University Committee on Use and Care of
Animals at the University of Michigan and conform to their relevant
regulatory standards.
Results
ERG Overexpression Confers Radioresistance that Is
Preferentially Reversed by PARP1 Inhibition
Given our previous identification of an interaction between ERG
and PARP1 [15], we aimed to assess our hypothesis that ERG over-
expression may confer radioresistance and that this radioresistance
might be preferentially overcome through PARP1 inhibition. We
have previously shown that the conserved ETS domain of ERG is
essential for the ERG-PARP1 interaction and that an ERG mutant
containing an ETS domain deletion no longer interacts with PARP1
[15]. Having established a lack of interaction between mutated ERG
and PARP1, the mutated ERG model previously described was used
as the control in this study. Lentiviral approaches were used to estab-
lish isogenic models of ERG overexpression (ERG+) and mutated
ERG overexpression (control) in PC3 and DU145 prostate cancer
cell lines (Figure 1A). To determine if ERG overexpression confers
radioresistance, clonogenic survival was compared between ERG+
and control cells in the PC3 (Figure 1B) and DU145 (Figure 1C )
cell lines with increasing doses of RT. ERG+ cells had a 1.25
(±0.07)-fold increase (mean ± SEM) in clonogenic survival compared
to control cells in the PC3 and DU145 cell lines, suggesting that over-
expression of ERG does indeed confers radioresistance (Figure 1D).
Next, cells were treated with noncytotoxic concentrations of olaparib
(0.5 μM for 1 hour), immediately preceding RT, treated with radia-
tion, and again assessed for clonogenic survival to evaluate if PARP1
inhibition would result in radiosensitization in ERG+ cells. The com-
bination of olaparib with radiation resulted, preferentially, in a sub-
stantial decrease in clonogenic survival for ERG+ cells in both cell
lines (Figure 1, B–C ). The RER of the PARP1 inhibitor was approx-
imately 1.52 (±0.03) (P < .05) in both cell lines with ERG over-
expression (Figure 1E ).
While PARP1 is responsible for the majority of all PARP activities,
we wanted to specifically address the contribution of inhibition of
PARP1 by olaparib using two independent siRNAs to selectively
deplete PARP1 from ERG+ and control cells in both the PC3 and
DU145 cell lines and then assess survival following radiation through
clonogenic assay. Knockdown of PARP1 with PARP1-specific siRNA
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resulted in decreased PARP1 levels in ERG+ and control cells in both
cell lines, whereas the nonspecific siRNA did not decrease PARP1
levels (Figure 1F ). Relative to nonspecific siRNA-treated cells,
PARP1 knockdown significantly sensitized ERG+ cells to radiation,
as demonstrated by a preferential decrease in clonogenic survival for
ERG+ cells in both cell lines (Figure 1, G–H ). PARP1 knockdown
resulted in an RER of 1.31 (P < .05) and 1.43 (P < .05) in the
PC3 and DU145 cell lines, respectively (Figure 1I ). Depletion of
PARP1 marginally decreased clonogenic survival in the control cells
(Figure 1, G–H ). These results were PARP1-specific as similar find-
ings were obtained when using a second PARP1 siRNA in DU145
and PC3 cells (see Figure W1).
PARP Activity Is Increased in ERG-Positive Cells
To explore the mechanism of ERG-mediated radioresistance that
was preferentially overcome through PARP inhibition, we assessed
whether ERG overexpression results in increased PARP activity.
In vitro histone ribosylation assays revealed that the rate of PAR syn-
thesis catalyzed by cell extracts from ERG+ cells in the PC3 and
DU145 was increased compared to control cells (Figure 2, A and B).
Consistent with this result, PAR levels were significantly increased
in ERG-overexpressing cells. Treatment with 0.5 μM olaparib for
24 hours resulted in decreased levels of PAR, with no alteration in
ERG and PARP1 expression (Figure 2B). Taken together, these find-
ings demonstrate that ERG overexpression increases PARP activity
and that this increased activity can be reversed with the PARP1
inhibitor olaparib.
Indirect Reversal of PARP Activity Preferentially
Radiosensitizes ERG+ Cells
Following its activation and autophosphorylation, PARP1 disso-
ciates from DNA strand breaks through charge repulsion [30]. The
PAR chains generated by PARP1 are then rapidly degraded by
PARG. As ERG+ cells were shown to have increased PARP1 activity,
we sought to indirectly reverse the activity of PARP1, through deg-
radation of PAR formed by PARP1 with PARG, and determine if
this reversal would also result in radiosensitization of ERG+ cells.
The isogenic models of ERG overexpression in the PC3 cell line were
modified to create lines with and without overexpression of PARG.
As anticipated, overexpression of PARG resulted in decreased PAR
levels in ERG+ cells without altering overall levels of ERG (Figure 2C).
PARG overexpression additionally reversed ERG-mediated radio-
resistance as shown by clonogenic assay (Figure 2D), consistent with
our finding that PARP1 inhibition with olaparib preferentially reverses
ERG-mediated radioresistance.
ERG Overexpression Promotes Increased DNA Repair
Following RT that Is Reversed by PARP Inhibition
Having established that ERG+ status confers radioresistance that is
preferentially overcome through direct and indirect PARP1 inhibition,
Figure 1. Reduced clonogenic survival of ERG-overexpressing cells (ERG+) after PARP inhibition. As the ETS domain of ERG is essential
for the ERG-PARP1 interaction, we established isogenic cell line models of ERG overexpression (ERG+) and mutated ERG overexpression
(control) (in which the ETS domain of ERG had been deleted). (A) Western blot analysis of ERG overexpression in PC3 and DU145 prostate
cancer cell lines. PC3 cells (B) and DU145 cells (C) were pretreated with 0.5 μM olaparib for 1 hour immediately before IR and then were
processed for clonogenic survival 24 hours post-IR. Data are from a single experiment representative of four independent experiments.
The effect of ERG overexpression on radioresistance is depicted in D and demonstrates the ability of ERG overexpression to induce
radioresistance. After treatment with PARP inhibitor, ERG+ cells are significantly radiosensitized (E). The mean RERs from four indepen-
dent experiments ± SEM are depicted (E). Additionally, knockdown of PARP1 induces radiation sensitivity in ERG+ cells. Levels of PARP1
protein in total cell extract from cells transfected with NT and PARP-1 siRNA are shown in F. PC3 (G) and DU145 (H) cell lines were treated
with PARP1-specific siRNA and NT siRNA, irradiated at 72 hours post-transfection, and then processed for clonogenic survival. Data are
from a single experiment representative of three independent experiments. The mean RERs from four independent experiments ± SEM
are depicted in I from ERG+ and control cells.
1210 Targeted Radiosensitization of ETS Fusion–Positive Prostate Cancer Han et al. Neoplasia Vol. 15, No. 10, 2013
we sought to further elucidate the means by which ERG overexpression
promotes radioresistance. As radiation causes DNA damage and acti-
vation of DNA damage responses, we assessed whether ERG+ cell lines
had enhanced ability to repair ionizing radiation (IR)–induced DNA
damage, and subsequently, if this enhanced repair response could be
inhibited or reversed through PARP1 inhibition. DNA damage and
repair in ERG+ and control cells treated with and without PARP1
inhibition was analyzed using neutral (Figure 3A) and alkaline
(Figure 3D) COMET assays in the DU145 cell line. Using neutral
COMET assays to directly measure DNA double-strand breaks and
repair, imaging at 30 minutes after a single 15-Gy dose of RT demon-
strated decreased DNA damage in ERG+ cells (Figure 3A). Mean tail
moments decreased with increasing time following RT in the ERG+
group compared to the control group. These mean tail moments were
statistically different at 10, 30, and 45 minutes following RT, consis-
tent with increased efficiency of short-term DNA repair in ERG+ cells
(Figure 3, B and C ). Pretreatment with 1.0 μM olaparib for 1 hour
before irradiation significantly slowed DNA repair in ERG+ cells,
resulting in increased mean tail moments that were dramatically greater
than those of the control group (Figure 3C).
One of the earliest events during single-strand break repair (SSBR)
is the rapid synthesis of PAR, followed by its rapid degradation by
PARG. Because PARP1 activity is increased in ERG-overexpressing
cells, we hypothesized that ERG overexpression may increase SSBR.
To specifically measure whether overexpression of ERG increases
DNA SSBR, we treated cells with H2O2, a single-strand break gener-
ator, and then performed alkaline COMET assays. ERG-overexpressing
cells exhibited significantly higher rates of DNA SSBR (Figure 3D).
Treatment with olaparib resulted in slower rates of SSBR in ERG-
overexpressing cells than the control cells, with significant differences
in mean tail length at 8, 15, and 30 minutes following treatment with
H2O2 (Figure 3, E and F). Results from the PC3 cell line can be found
in Figure W2 and are consistent with the findings in the DU145 cell
line. To confirm that SSBR contributes to ERG-mediated radioresis-
tance, we used siRNA approaches to knock downXRCC1, a key protein
involved in DNA SSBR including the base excision pathway [31], in
both ERG+ and ERG− PC3 prostate cancer cells (Figure W2F ) and
performed clonogenic survival assays assessing radiation response in
these cells (Figure W2E ). As shown, XRCC1 knockdown results in
partial reversal of the radiation resistance (Figure W2E). These findings
suggest that both single- and double-stranded DNA repairs contribute
to ERG-mediated radiosensitization by PARP1 inhibition. Together,
these results support the conclusion that ERG overexpression increases
DNA repair and that PARP1 inhibition preferentially reverses this
enhanced DNA repair in ERG-overexpressing cells.
We next assessed the presence of unrepaired DNA damage asses-
sing γ-H2AX foci in ERG+ and control DU145 cells treated with a
single 2-Gy dose of RT. RT was administered in the absence and
presence of PARP1 inhibition. Treatment with radiation produced
γ-H2AX foci as early as 30 minutes post-irradiation, which resolved
Figure 2. PARP activity is increased in ERG+ cells, and overexpression of PARG reverses ERG-mediated radiation resistance. (A) PARP
activity assay using Trevigen kits shows that PARP activity is increased in ERG+ PC3 and DU145 cells compared to controls. (B) Western
blot analysis of PAR in ERG+ and control cells. Cells were treated with 0.5 μM olaparib for 24 hours and then processed for immunoblot
analysis. Treatment with olaparib resulted in decreased levels of PAR, with no alteration in ERG and PARP1 levels. Overexpression of
PARG reverses ERG-mediated radiation resistance. (C) PAR levels are reduced in PC3 ERG+ cells with concomitant PARG overexpression.
(D) In ERG+ cells, concomitant overexpression of PARG leads to reduced clonogenic survival in PC3 cells.
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to baseline levels over time. The quantity of γ-H2AX foci were mea-
sured at baseline and then 30 minutes, 2, 6, and 24 hours following
RT. In the cells treated with RT in the absence of PARP1 inhibition,
ERG+ cells had significantly decreased levels of γ-H2AX compared to
the control group at 24 hours post-RT (Figure 4, A–C ). The number
of cells with >10 γ-H2AX foci were quite similar in the control and
ERG+ cells without PARP1 inhibition at 30 minutes and 2 hours
following RT. However, as time progressed to 6 and 24 hours
post-RT, the ERG+ cells showed dramatically quicker resolution of
γ-H2AX foci compared to the control cells (Figure 4B), consistent
with improved long-term DNA repair in ERG+ cells.
Pretreatment of cells with 1.0 μM olaparib for 1 hour immediately
before RT resulted in preferential reversal of the increased DNA
repair efficiency conferred by ERG overexpression, as indicated by a
significant prolongation of γ-H2AX signaling in ERG-overexpressing
cells. PARP1 inhibition with olaparib repressed DNA repair more
profoundly in ERG-positive cells than the control cells (Figure 4C ).
Results from the PC3 cell line can be found in Figure W3 and are
consistent with the findings in the DU145 cell line. These findings
suggest that PARP1 inhibition not only preferentially reverses ERG+
mediated accelerated DNA repair but also decreases DNA repair
efficiency compared to control ERG− cells treated only with RT.
Preferential Radiosensitization of ERG+ Cells by PARP1
Inhibition Is Not Due to Cell Cycle Redistribution
Because changes in cell cycle distribution can impact radiosensitiv-
ity, we analyzed cell cycle profiles for ERG+ and control cells in the
PC3 and DU145 cell lines treated in the absence and presence of
olaparib, both before RT and at 24 hours following a single 4-Gy
dose of RT (Figure W4). ERG+ cells did not differ from control cells
in baseline cell cycle distribution. Additionally, in both ERG+ and
control cells, the addition of the PARP1 inhibitor did not affect cell
Figure 3. PARP1 inhibition delays DNA double-strand repair as measured by neutral COMET assay and DNA SSBR by alkaline COMET
assay. DU145 cells were pretreated with 1.0 μM olaparib for 1 hour before IR (15 Gy) and then processed for neutral COMET assay (A–C)
or treated with 100 μMH2O2 in PBS for 20 minutes on ice and then processed for alkaline COMET assay (D–F). (A) Representative image
(from neutral COMET assays) of cells under each condition at 30 minutes post-radiation is presented. (B) Quantification of the tail
lengths from each condition was calculated from a minimum of 100 cells for each data point. Data are the means ± SEM of three
independent experiments. (C) Relative fold change of tail moments by PARP inhibition (comparing mean tail moments following PARP
inhibition and radiation versus radiation alone). (D) Representative image (from alkaline COMET assays) of cells under each condition at
15minutes post-treatment is presented. (E) Quantification of the tail lengths fromeach conditionwas calculated fromaminimumof 100 cells
for eachdatapoint. Data are themeans±SEMof three independent experiments. (F) Relative fold changeof tailmoments byPARP inhibition.
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cycle distribution before the administration of RT. Together, these
findings demonstrate that the preferential radiosensitization of ERG+
cells by olaparib is not due to cell cycle redistribution. Olaparib-treated
cells demonstrated an increase in G2/M arrest following radiation,
consistent with the expected response to increased DNA damage.
ERG Overexpression Confers Radioresistance In Vivo that
Is Preferentially Reversed by PARP Inhibition
Lastly, we assessed ERG conferred radioresistance and the effect of
PARP1 inhibition on this radioresistance using PC3 ERG+ and PC3
control mouse xenograft models. For these experiments, we selected
the PARP1 inhibitor ABT-888, as this agent is being combined with
cytotoxic agents in ongoing clinical trials specific to prostate cancer
(www.clinicaltrials.gov). Two weeks following engraftment, ERG+
and control xenografts were treated with ABT-888 twice daily alone,
radiation alone (2 Gy/day for 5 days), or both treatments in combi-
nation. Tumor size was measured three times per week for 6 weeks.
Eight animals were included in each treatment and control group.
After completion of follow-up, time to tumor volume doubling
was calculated for each group (Figure 5). The ERG+ and control
groups that received no treatment experienced the fastest increase
in tumor volume. In both groups, nearly all xenografts doubled in
tumor volume by day five. These same two groups treated with
ABT-888 alone had the next most rapid increase in tumor volume.
In both the ERG+ and control groups receiving ABT-888, nearly all
Figure 4. The effects of olaparib on γ-H2AX in ERG-positive and ERG-negative cells. DU145 cells were pretreated with 1.0 μM olaparib
for 1 hour before IR (2 Gy) and then fixed for immunofluorescence. (A) Representative image of cells under each condition at 24 hours
post-radiation is presented. Cells were stained with 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI; blue) and γ-H2AX (red).
(B) Quantification of the foci from each condition was calculated from a minimum of 100 cells for each data point. Data are the mean
of three independent experiments ± SEM. (C) Relative fold change in percentage of cells with >10 γ-H2AX foci.
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xenografts had doubled in tumor volume by day 20 of treatment. RT
significantly prolonged the tumor volume doubling time in both
groups; however, the control group treated with RT achieved a better
response to RT than the ERG+ group, as one half of the animal mod-
els with ERG+ xenografts doubled in tumor volume by day 30,
whereas only two xenografts from the control group doubled in
tumor volume over the entire course of follow-up. The group with
the overall best outcome following treatment were the ERG+ xeno-
grafts treated with RT and ABT-888, as not a single xenograft in this
group doubled in tumor volume by 6 weeks after treatment initia-
tion. These in vivo findings confirm the findings from the in vitro
analyses, suggesting that ERG+ status confers radioresistance, and
that this radioresistance can be overcome through inhibition of
PARP1. As final confirmation, PAR formation was assessed in tumor
xenografts, which again showed increased PAR formation in ERG+
cells that was reversed through PARP inhibition (Figure 5B).
Discussion
In this study, we have demonstrated that ERG overexpression results
in radioresistance that is preferentially overcome through PARP inhib-
ition. ERG overexpression resulted in increased PARP1 activity that
subsequently led to an increased efficiency of short- and long-term
DNA repairs. Inhibition of PARP1 with the PARP inhibitor olaparib
prevented enhanced DNA repair, leading to radiosensitization, with-
out altering cell cycle distribution before treatment with RT. These
findings were replicated in an in vivo xenograft model. These results
highlight that PARP1 inhibition may be a reasonable means of induc-
ing radiosensitization in cancers overexpressing ETS transcription
factors, which we demonstrated confer radioresistance (see Figure 6).
This has significant implication, as many cancers known to over-
express ETS transcription factors are treated with RT, including pros-
tate cancer, where close to 50% of cancers harbor ETS gene fusions.
Thus, a significant number of patients with ETS-driven radioresistant
tumors may potentially benefit from the preferential radiosensitization
promoted through PARP1 inhibition.
The presence of ETS gene fusions in prostate cancer has not con-
sistently been demonstrated to be associated with patient outcomes.
Two studies assessing outcomes in non–prostate-specific antigen
(PSA)–screened watchful waiting cohorts found that patients harbor-
ing ETS gene fusions were at higher risk for prostate cancer–specific
mortality [32,33]. Many retrospective analyses have also assessed the
clinical impact of ETS gene fusion status following radical prostatec-
tomy in PSA-screened populations, with variable results. Several have
identified an association between the presence of ETS gene fusions
and increased risk for PSA recurrence following radical prostatectomy
[34–37], while others have noted no association [4,38–41], or even
improved outcomes in the presence of ETS gene fusions [42,43].
These conflicting results make it difficult to draw conclusions
concerning the clinical implications associated with positive ETS
gene fusion status following radical prostatectomy. More recently,
ETS factors have been proposed to cause subtle transcriptional
changes to the androgen receptor (AR) cistrome [44,45], which
may be dependent on the presence of additional genetic lesions
[44], suggesting that the interpretation of the associative value of
ERG with clinical outcome may also be confounded by the presence
of additional genetic lesions.
The uncertainty surrounding the prognostic ability of ETS gene
fusions following radical prostatectomy or watchful waiting does
not lessen their potential as predictive biomarkers in the setting of
Figure 6. Proposed mechanism whereby ETS gene fusions lead to
an increase in ERG transcription factor activity, upregulating
PARP1 activity and increasing DNA repair efficiency after IR, leading
to effective radioresistance in prostate cancer. Our data demon-
strate that PARP inhibition abrogates the radioresistance conferred
by ETS gene fusions and may be an effective strategy to overcome
this radioresistance.
Figure 5. ERG overexpression confers radiation resistance in vivo,
which is reversed with PARP inhibition. Two weeks after engraft-
ment, PC3 ERG+ and control xenografts were treated with ABT-
888 (100 mg/kg twice daily) alone, radiation alone (2 Gy for 5 days),
or in combination. The cumulative incidence plot depicts the per-
centage of tumors in each treatment group that have doubled in
volume as a function of time. (A) ERG overexpression confers ra-
diation resistance as shown by a shorter time needed for ERG+
tumors to achieve volumetric doubling than the control tumors.
ERG overexpression causes sensitivity to PARP inhibition that is
enhanced in combination with radiation treatment. (B) Western
blot analysis of ERG+ PC3 cell xenografts treated with or without
100 mg/kg ABT-888 for 4 hours before harvesting. Total PAR, ERG,
PARP1, and actin were assessed.
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radiation. In fact, it is likely that predictive biomarkers for RT would
indeed differ from prognostic biomarkers following radical prosta-
tectomy or watchful waiting, as prognosticators following surgery
or observation are potentially prognostic independent of therapy.
Despite their potential, limited data exist regarding the ability of
ETS gene fusions to predict response to RT. Given that approxi-
mately 50% of patients with prostate cancer, as well as patients with
other cancers, overexpress ETS transcription factors and are treated
with RT, the ability to predict response to RT from these biomarkers
is clinically relevant and may assist in guiding therapy and future
decision making, particularly in the context of more aggressive pros-
tate cancers. Similar to the inconsistent findings in prostatectomy
series, Swanson et al. found that the presence of the TMPRSS2:ERG
fusion resulted in radiosensitization in PC3 prostate cancer cells and
radioresistance in DU145 prostate cancer cells [46]. The methods used
to select cells for clonogenic survival in their analysis may provide a
possible explanation for their conflicting findings. Clonogenic survival
was performed on single monoclonal cell populations from cell lines
[46]. By using a highly selected monoclonal population as opposed
to a polyclonal cell population, it is difficult to discern whether the
findings regarding radiosensitivity are truly a reflection of ETS status
or due to other unknown genetic confounders of the clone. Our find-
ings in polyclonal cell populations from both the PC3 and DU145
prostate cancer cell lines suggest that the presence of ETS gene fusions
does confer radioresistance and that this radioresistance can be prefer-
entially overcome with PARP inhibition.
As the prototypical ETS gene fusion in prostate cancer, TMPRSS2:
ERG, combines the androgen-responsive transmembrane protease
TMPRSS2 with the ETS family member ERG, we intentionally per-
formed our analyses in the AR-negative prostate cancer model cell
lines PC3 and DU145 to differentiate the effects of PARP inhibition
on ETS+ cell lines from AR-related effects. Androgens and the AR
play an integral role in normal prostate tissue differentiation and
function, as well as in prostate carcinogenesis and progression [47].
Androgen deprivation therapy (ADT) is commonly employed as
treatment for both localized and metastatic prostate cancer. Addition-
ally, ADT is a standard component of treatment for high-risk prostate
cancer patients receiving RT. Multiple phase III clinical trials have
shown improved survival in this population with the addition of
ADT to RT [48,49]. However, the underlying mechanism by which
ADT synergistically interacts with RT to improve outcomes is not
fully understood. More recently, androgen stimulation has been
implicated in the formation of ETS gene fusions in prostate cancer
by inducing genomic spatial rearrangements and DNA breaks that
promote these fusions [50–52]. ETS gene fusions have also been
demonstrated to modulate androgen signaling in prostate cancer
[44,45] but in a context-specific manner based on the genetic back-
ground. Given the known interactions between the AR and ETS gene
fusions in prostate cancer, it is not unreasonable to hypothesize that
the mechanism through which ADT administration concurrently
with RT improves outcomes for high-risk prostate cancer patients is
through an ETS gene fusion–AR interaction. Future research is needed
to clearly define the mechanism by which ADT improves RT outcomes
and if this is dependent on an ETS gene fusion–AR interaction.
In addition to the interaction between ETS gene fusions and the
AR, we have previously identified an interaction between these gene
fusions and PARP1 [15], which led to our hypothesis that ETS over-
expression results in radioresistance that might be overcome through
PARP inhibition. Herein, we confirm our hypothesis, further estab-
lishing an ETS-PARP relationship. While others, including us, have
previously demonstrated that PARP1 inhibition adds to the effective-
ness of cytotoxic therapies in ETS fusion–positive cancers [15,53–55],
our study is the first to employ both genetic knockdown and pharma-
cologic inhibition to prove the specificity of this finding, to demon-
strate a mechanism through increased PARP1 activity resulting in
increased DNA repair efficiency, and to demonstrate this finding
in prostate cancer in vivo. Along with the interaction with ETS gene
fusions, PARP has also been shown to interact with the AR, assisting
in AR transcriptional activity and overall function [24]. Therefore,
PARP inhibition may serve as a potential strategy to simultaneously
target ETS overexpression and aberrant AR function in prostate cancer
and thereby improve outcomes in patients with prostate cancer treated
with RT. Further work is required to elucidate the exact mechanisms
through which PARP and ETS gene fusions interact, but clearly, PARP
inhibition has the potential to significantly improve radiation results in
prostate cancer, as well as other ETS-overexpressing tumors treated
with RT.
In summary, our findings suggest that ETS overexpression results
in radioresistance and that PARP inhibition serves as a potentially
novel strategy to improve patient outcomes following RT for tumors
with ETS overexpression. These findings gain further clinical rele-
vance given that ETS gene fusions serve as strong biomarkers. First,
they are highly specific, as ETS gene fusions and resultant overexpres-
sion does not occur in normal tissue. Additionally, ETS gene fusion
status can be determined through tissue biopsy and, in the case of
prostate cancer, can be detected through noninvasive urine assays,
allowing for easy identification of patients with inherently radioresis-
tant tumors [56]. Finally, while transcription factor rearrangements,
such as ETS gene fusions, are pharmacologically difficult to target
directly, we show that PARP inhibition is a viable method to reverse
the radioresistance generated through ETS overexpression. Clinical
trials targeting ERG overexpression with the addition of PARP inhib-
ition to RT are needed, as is further revelation of the mechanisms
through which ETS gene fusions and PARP interact. Reversal of
radioresistance through PARP inhibition in patients identified to
harbor tumors with ETS gene fusions would be a significant step
in the direction toward personalized cancer therapy.
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Figure W1. Reduced clonogenic survival of ERG+ cells after PARP inhibition. Using a second siRNA designed against PARP1, we con-
firm our initial findings presented in Figure 1, G to I . Levels of PARP1 protein in total cell extract from cells transfected with NT and
PARP-1 siRNA#2 are shown in C. PC3 (A) and DU145 (B) cell lines were treated with PARP1-specific siRNA#2 and NT siRNA, irradiated
at 72 hours post-transfection, and then processed for clonogenic survival, with surviving fraction depicted in the figure. Data are from a
single experiment representative of three independent experiments. The mean RERs from four independent experiments ± SEM are
depicted in D from ERG+ and ETS domain–deleted control cells.
Figure W2. PARP inhibition delays DNA double-strand repair as measured by neutral and alkaline COMET assays. (A–B) PC3 cells were
pretreated with 1.0 μM olaparib for 1 hour before IR (10 Gy) and then processed for neutral COMET assays. Quantification of the tail
lengths from each condition was calculated from a minimum of 100 cells for each data point. Data are the means ± SEM of three
independent experiments. (C–D) PARP inhibition also delays DNA single-strand repair as measured by alkaline COMET assay. PC3 cells
were pretreated with 1.0 μM olaparib for 1 hour and then were treated with 100 μM H2O2 in PBS for 20 minutes on ice. The cells were
collected after the indicated repair period in H2O2-free medium and then were processed for alkaline COMET assay. Quantification of
the tail lengths from each condition was calculated from a minimum of 100 cells for each data point. Data are the means ± SEM of three
independent experiments. (E) PC3 ERG+ and control cells were treated with XRCC1-specific siRNA and NT siRNA, irradiated at 72 hours
post-transfection, and then processed for clonogenic survival, with surviving fraction depicted in the figure. Levels of XRCC1 protein in
total cell extract from cells transfected with NT and XRCC1 siRNA are shown in F. Data are from a single experiment representative of
three independent experiments.
Figure W3. The effects of olaparib on γ-H2AX in ERG+ and control
cells. PC3 cells were pretreated with 1.0 μM olaparib for 1 hour
before IR (2 Gy) and then fixed for immunofluorescence. (A) Rep-
resentative image of cells under each condition at 24 hours post-
radiation is presented. Cells were stained with DAPI (blue) and
γ-H2AX (red). (B) Quantification of the foci from each condition was
calculated from aminimum of 100 cells for each data point. Data are
the means of three independent experiments ± SEM. (C) Relative
fold change in percentage of cells with >10 γ-H2AX foci.
Figure W4.Olaparib increases radiation-induced G2 arrest. Cells were treated with olaparib for 1 hour pre-RT (4 Gy) and for 16 to 24 hours
post-RT. Cells were analyzed for DNA content at pre-RT and 16 and 24 hours post-RT. Data are the means of three independent
experiments ± standard error.
